Terlipressin Side Effects: Safety Signals and Warnings
Terlipressin safety concerns are compound-specific. The main listed side effects are Abdominal pain and cramping, Diarrhea, and Respiratory failure. The main warning signals are Serious ischemic events (coronary, peripheral, mesenteric) - contraindicated in significant coronary, peripheral, or mesenteric vascular disease, Respiratory failure - monitor oxygenation; increased risk in patients with volume overload, and Do not use if serum creatinine >5.0 mg/dL or on dialysis.
Direct Answer
Terlipressin (Terlivaz) is FDA-approved for hepatorenal syndrome type 1 - a life-threatening complication of advanced cirrhosis - with Phase 3 data from the CONFIRM trial showing significant reversal of HRS-1 versus placebo. As the first FDA-approved treatment specifically for HRS-1, it represents a meaningful regulatory milestone. Respiratory failure risk in high MELD patients is a real safety consideration that limits its use.
- Evidence grade
- Level A
- Research status
- FDA Approved
- Category
- Healing & Recovery
- Best for
- Hepatorenal syndrome type 1 (HRS-1), vasopressin V1 receptor agonism, portal hypertension research
Reported Side Effects
- Abdominal pain and cramping
- Diarrhea
- Respiratory failure
- Skin necrosis and peripheral ischemia
- Bradycardia
- Hyponatremia
Warnings
- Serious ischemic events (coronary, peripheral, mesenteric) - contraindicated in significant coronary, peripheral, or mesenteric vascular disease
- Respiratory failure - monitor oxygenation; increased risk in patients with volume overload
- Do not use if serum creatinine >5.0 mg/dL or on dialysis
- Hyponatremia - monitor serum sodium
- QT prolongation - ECG monitoring recommended
Known or Plausible Interactions
- Vasoconstrictors and vasopressors (additive ischemic risk)
- QT-prolonging drugs (additive cardiac risk)
- Octreotide (may be used in combination for variceal bleeding)
- Beta-blockers (additive bradycardia, but non-selective beta-blockers used in portal hypertension)
Regulatory Context
FDA-approved (September 2022) for hepatorenal syndrome with rapid reduction in kidney function. Marketed as Terlivaz by Mallinckrodt. Used outside the US (as Glypressin) for variceal bleeding for decades.
Evidence Snapshot
| Evidence grade | Level A |
|---|---|
| Research status | FDA Approved |
| Best supported outcomes | Hepatorenal Syndrome Reversal (Level A), Variceal Bleeding Control (Level A), and Ischemic Complications (Level A) |
| Primary citation count | 3 |
| Last reviewed | 2026-04-04 |
Related Guides
How to Cite This Page
ExaminePeptides. "Terlipressin Side Effects: Safety Signals and Warnings." Last reviewed 2026-04-04. https://examinepeptides.com/answers/terlipressin-side-effects-safety/
This static answer page is built for fast indexing and direct citation. It summarizes the matching full evidence review and links back to primary sources where the source database includes them.